PPARGC1A and androgen insensitivity syndrome: Next, XCT790 was used to treat the PGC-1αf/f and mPGC-1α mice with AIS, and we found that the PGC-1α-induced reduction in neurological deficits could be reversed by XCT790 administration (Additional file 2: Fig. S15i-k).